DPK 060

Drug Profile

DPK 060

Alternative Names: DPK-060

Latest Information Update: 17 Dec 2015

Price : $50

At a glance

  • Originator DermaGen
  • Developer DermaGen; Pergamum
  • Class Antimicrobial cationic peptides
  • Mechanism of Action Cell membrane permeability enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Atopic dermatitis; Otitis externa

Most Recent Events

  • 02 Oct 2015 No recent reports of development identified - Phase-II for Otitis externa in Sweden (Topical)
  • 31 Dec 2012 Top-line efficacy and tolerability data from a phase II trial in Otitis externa released by Karolinska Development and Pergamum
  • 31 Oct 2011 Phase-II clinical trials in Otitis externa in Sweden (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top